Introduction {#sec1-1744806918762205}
============

Psoriasis, characterized by quick and excessive growth of the skin's epidermal layer,^[@bibr1-1744806918762205]^ is a common, chronic, and systemic disease, affecting 1--3% of the world population. It is widely considered as a genetic disease and could be affected by some environmental factors.^[@bibr2-1744806918762205]^ Up to now, various therapies are available for psoriasis, including phototherapy, topical treatment, systemic therapies, and biologic drugs.^[@bibr3-1744806918762205]^

The biologic drugs can be classified into five classes based on their mechanism: anti-metabolites (AM), anti-tumor necrosis factor-α agent (anti-TNF-α), anti-T-cell agent (ANT), anti-interleukin-12/23 agents (anti-IL12/23), and anti-interleukin-17 agents (anti-IL17). It is reported that methotrexate, an AM, has been applied as a valid systemic treatment for psoriasis patients over 48 years.^[@bibr4-1744806918762205]^ However, it is relevant to hepatotoxicity and myelosuppression.^[@bibr5-1744806918762205]^ Besides, the TNF is widely regarded as an important cytokine involved in the pathophysiology of psoriasis. Therefore, monoclonal antibodies, such as adalimumab and infliximab, which antagonized TNF, were applied in the treatment of psoriasis.^[@bibr6-1744806918762205],[@bibr7-1744806918762205]^

Relevant studies showed that psoriasis was possibly an autoimmune disease where the activation of skin-directed T-cells performed an important role.^[@bibr8-1744806918762205]^ Alefacept, a recombinant protein, has the ability to block T-cell's proliferation and activation by combining with CD2 on the surface of T-cells. Alefacept can also induce selective CD45RO+ T-cell apoptosis by interacting with the immunoglobulin receptors FcγRIII on the accessory cells.^[@bibr9-1744806918762205]^ Other drugs, such as efalizumab and itolizumab, are humanized monoclonal antibodies which could directly deal with the pathogenic T-cells by binding to CD11a or CD6 and inhibit T-cell functions, such as activation, trafficking, and migration.^[@bibr10-1744806918762205][@bibr11-1744806918762205]--[@bibr12-1744806918762205]^

Meanwhile, it has been discovered that TNF is produced by the immune pathways stimulated by two interleukins, interleukin-12 (IL-12) and interleukin-23 (IL-23).^[@bibr13-1744806918762205]^ This discovery indicates that both IL12 and IL23 play a pivotal role in the psoriasis development. In addition, IL-17A and IL-17RA were also found related to the disease severity because of the elevated levels of IL-17A in the diseased skin and blood of patients with psoriasis.^[@bibr14-1744806918762205]^ Etanercept, a human fusion TNF soluble receptor, is used to prevent the TNF-mediated inflammatory response and applied for the therapy of psoriatic arthritis and chronic plaque.^[@bibr15-1744806918762205]^

To make an effective and safe decision in treatment of psoriasis, it is necessary to conduct reliable evidences of comparison among these drugs. A number of traditional meta-analysis studies had been done to make comparison between two therapies, which indicated that all the therapies are more effective than placebo (PBO). But they cannot compare several therapies simultaneously. Therefore, the network meta-analysis (NMA) is required to synthesize all valuable evidences from randomized control trials (RCTs), combining both direct and indirect evidences, to convincingly draw the conclusions about competitive efficacy and safety information.

Woolacott et al. made the comparisons among three biological therapies, efalizumab, infliximab, and etanercept, and two nonbiological therapies.^[@bibr16-1744806918762205]^ Adalimumab was taken into consideration in the work of Bansback et al.^[@bibr17-1744806918762205]^ After then, with the development of biological treatment, more NMA were conducted, such as the works of Reich et al.^[@bibr18-1744806918762205]^ and Lin et al.,^[@bibr19-1744806918762205]^ who added the ustekinumab, which antagonizes IL-12/23p40. Besides, Nast et al.^[@bibr20-1744806918762205]^ assessed the efficacy and safety of treatments of systemic long-term treatments. Recently, Gomez-Garcia et al.^[@bibr21-1744806918762205]^ used the new 2015 PRISMA statement for the NMA and evaluated the comparative short-term efficacy and tolerance of the agents. Jabbar-Lopez et al. established the relative efficacy and tolerability of six monoclonal antibodies. None of them compared the biotics from the level of large classes.

The primary objective of our study was to give an extension to the existing NMAs to evaluate the efficacy and safety of different treatment agents. More agents were taken in account to provide more reliable conclusion. Moreover, the ranking possibility in specific efficacy and safety were also presented to help making optimal decision in clinical drug using. Besides, no NMA similar to this study, with sufficient samples and consideration of all therapies, had been done yet.

Materials and methods {#sec2-1744806918762205}
=====================

Search strategy {#sec3-1744806918762205}
---------------

To get the relevant studies, the following three electronic databases were taken into our retrieval: Chinese National Knowledge Infrastructure, PubMed, and Embase. Regardless of the limitation of language, key terms "psoriasis," "antimetabolites," "macrolides," "antibodies, monoclonal," "etanercept" as well as their acronyms were searched in this work. Besides, the reference lists were examined to identify the potentially available studies.

Inclusion and exclusion criteria {#sec4-1744806918762205}
--------------------------------

All included trials must satisfy the following criteria: (i) the studies must be RCTs; (ii) the patients involved in the studies must be diagnosed as psoriasis; and (iii) relevant outcomes should be contained. Besides, duplicate RCTs or the studies with isolated comparison were excluded.

Outcome measure and data extraction {#sec5-1744806918762205}
-----------------------------------

Data extraction was conducted by two reviewers independently, and following characteristics of each study were extracted from the original documents: (i) the basic information, including the first author, country, published year, and blinding; (ii) the patients characteristics, including ages, gender ratio, and disease duration; (iii) efficacy outcomes, including the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician's Global Assessment (PGA); (iv) safety outcomes, including the incidence of all AEs, infection, nasopharyngitis, headache, and upper respiratory tract infection (URTI).

Statistical analysis {#sec6-1744806918762205}
--------------------

Odds ratio (OR) with corresponding 95% credible interval (CrI) were used to evaluate the binary outcomes. Mean difference with corresponding 95% CrI were applied to assess the continuous outcomes. Meanwhile, forest plots were drawn to visually present the relative efficacy and safety of different comparisons for each outcome. Consistency between direct and indirect comparison was analyzed by the node-splitting method. *p*\<0.05 indicated a significant inconsistency for a specific comparison. Moreover, surface under the cumulative ranking curves (SUCRAs) were calculated to present the ranking probability of each treatment to find the relatively optimal treatment to improve the efficacy and decrease the incidence of adverse events. Software R (version 3.2.3) and STATA (version 13.0) were used to implement the NMA.

Results {#sec7-1744806918762205}
=======

Included studies {#sec8-1744806918762205}
----------------

In the retrieval, 1562 records were identified at the beginning, and 17 records were added manually. Among them, 573 duplicates were removed, and 989 records were left. After 242 records excluded during screening, 432 records were full-text assessed. Finally, 75 studies and 25,108 patients were included in our NMA.^[@bibr4-1744806918762205][@bibr5-1744806918762205]--[@bibr6-1744806918762205],[@bibr9-1744806918762205][@bibr10-1744806918762205][@bibr11-1744806918762205][@bibr12-1744806918762205][@bibr13-1744806918762205]--[@bibr14-1744806918762205],[@bibr22-1744806918762205][@bibr23-1744806918762205][@bibr24-1744806918762205][@bibr25-1744806918762205][@bibr26-1744806918762205][@bibr27-1744806918762205][@bibr28-1744806918762205][@bibr29-1744806918762205][@bibr30-1744806918762205][@bibr31-1744806918762205][@bibr32-1744806918762205][@bibr33-1744806918762205][@bibr34-1744806918762205][@bibr35-1744806918762205][@bibr36-1744806918762205][@bibr37-1744806918762205][@bibr38-1744806918762205][@bibr39-1744806918762205][@bibr40-1744806918762205][@bibr41-1744806918762205][@bibr42-1744806918762205][@bibr43-1744806918762205][@bibr44-1744806918762205][@bibr45-1744806918762205][@bibr46-1744806918762205][@bibr47-1744806918762205][@bibr48-1744806918762205][@bibr49-1744806918762205][@bibr50-1744806918762205][@bibr51-1744806918762205][@bibr52-1744806918762205][@bibr53-1744806918762205][@bibr54-1744806918762205][@bibr55-1744806918762205][@bibr56-1744806918762205][@bibr57-1744806918762205][@bibr58-1744806918762205][@bibr59-1744806918762205][@bibr60-1744806918762205][@bibr61-1744806918762205][@bibr62-1744806918762205][@bibr63-1744806918762205][@bibr64-1744806918762205][@bibr65-1744806918762205][@bibr66-1744806918762205][@bibr67-1744806918762205][@bibr68-1744806918762205][@bibr69-1744806918762205][@bibr70-1744806918762205][@bibr71-1744806918762205][@bibr72-1744806918762205][@bibr73-1744806918762205][@bibr74-1744806918762205][@bibr75-1744806918762205][@bibr76-1744806918762205][@bibr77-1744806918762205][@bibr78-1744806918762205][@bibr79-1744806918762205][@bibr80-1744806918762205][@bibr81-1744806918762205][@bibr82-1744806918762205][@bibr83-1744806918762205][@bibr84-1744806918762205][@bibr85-1744806918762205][@bibr86-1744806918762205]--[@bibr87-1744806918762205]^ The flow chart was shown in [Figure 1](#fig1-1744806918762205){ref-type="fig"}. The details of specific treatment, the characteristics of patients, and outcomes of each trail were provided in [Table 1](#table1-1744806918762205){ref-type="table"}. The study sample sizes ranged from 33 to 1831. The follow-up period ranged from six weeks to 120 weeks. Among 58 trails, five trails failed to provide age range of the patients,^[@bibr27-1744806918762205],[@bibr29-1744806918762205],[@bibr49-1744806918762205],[@bibr59-1744806918762205],[@bibr62-1744806918762205],[@bibr70-1744806918762205]^ while six trails failed to provide gender ratios of the patients.^[@bibr14-1744806918762205],[@bibr27-1744806918762205],[@bibr49-1744806918762205],[@bibr59-1744806918762205],[@bibr70-1744806918762205],[@bibr86-1744806918762205]^ The mean disease duration was 17.5 years (range 5.6--22.8). Besides, disease severity was assessed containing all the trails with a baseline PASI score of 19.9 (range 5.5--33.1) and a body surface area (BSA) of 28.8% (range 5.1--49.8). Jadad score of included RCTs was shown in Table S1. Meanwhile, the network diagram was shown in [Figure 2](#fig2-1744806918762205){ref-type="fig"}. The area of dots represents the number of patients in the therapy, and the width of lines stands for the number of references including the comparison.

![PRISMA flow chart.\
RCTs: randomized control trials.](10.1177_1744806918762205-fig1){#fig1-1744806918762205}

###### 

Baseline population characteristics of included studies.

![](10.1177_1744806918762205-table1)

  Author           Year           Country         Follow-up      Type           Intervention    *N*    Age            Male (%)        Disease        HPA    Affected BSA (%)   PASI
  ---------------- -------------- --------------- -------------- -------------- --------------- ------ -------------- --------------- -------------- ------ ------------------ -------------
  Papp             2008           Canada          12 weeks       anti-IL12/23   Ustekinumab     820    45.1 ± 12.1    69.2            19.3 ± 11.7    26.2   25.9 ± 15.5        19.4 ± 6.8
  PBO              Placebo        410             47.0 ± 12.5    69             20.8 ± 12.2     25.6   26.1 ± 17.4    19.4 ± 7.5                                               
  Revicki          2008           USA             16 weeks       anti-TNF-α     Adalimumab      103    42.8 ± 12.3    64.1            17.6 ± 10.0    22.3   33.7 ± 20.0        20.1 ± 7.4
  AM               Methotrexate   108             41.9 ± 11.9    66.7           19.0 ± 10.3     17.6   32.6 ± 20.7    19.5 ± 7.4                                               
  PBO              Placebo        53              40.7 ± 11.4    67             18.9 ± 8.71     20.8   28.4 ± 16.1    19.2 ± 6.9                                               
  Blauvelt         2015           USA             12 weeks       anti-IL17      Secukinumab     118    45.1 ± 12.6    64.4            18.0 ± 11.9    --     33.3 ± 17.9        20.7 ± 7.9
  PBO              Placebo        59              46.5 ± 14.1    66.1           20.2 ± 14.2     --     32.2 ± 17.4    21.1 ± 8.5                                               
  Dubertret        2006           Germany         12 weeks       ANT            Efalizumab      529    44.0 ± 12.0    67.3            19.3 ± 11.5    --     37.1 ± 20.2        23.6 ± 6.7
  PBO              Placebo        264             45.3 ± 12.1    67.4           21.0 ± 10.2     --     36.2 ± 20.7    23.0 ± 9.6                                               
  Barker           2011           UK              16 weeks       anti-TNF-α     Infliximab      653    44.1 ± 33.9    67              18.8 ± 11.6    --     31.9 ± 16.5        21.4 ± 8.0
  AM               Methotrexate   215             41.9 ± 27.1    69             17.0 ± 10.3     --     31.0 ± 15.0    21.1 ± 7.6                                               
  Asahina          2010           Japan           16 weeks       anti-TNF-α     Adalimumab      123    47.7 ± 12.8    84.2            14.2 ± 9.29    --     43.3 ± 19.4        25.4 ± 8.9
  PBO              Placebo        46              43.9 ± 10.7    89.1           15.5 ± 8.83     --     46.7 ± 19.9    29.1 ± 11.8                                              
  Chaudhari        2001           USA             10 weeks       anti-TNF-α     Infliximab      22     35.1 ± 11.2    72.7            --             --     --                 26.6 ± 10.3
  PBO              Placebo        11              45.0 ± 12.0    72.7           --              --     --             20.3 ± 5.5                                               
  Gordon           2003           USA             12 weeks       ANT            Efalizumab      369    45.2 ± 14.3    68              19.1 ± 15.2    --     28.0 ± 21.2        19 ± 6.9
  PBO              Placebo        187             45.7 ± 13.7    71             19.0 ± 13.0     --     27.0 ± 20.0    19 ± 6.7                                                 
  Gottlieb         2004           USA             10 weeks       anti-TNF-α     Infliximab      198    44.1 ± 14.1    73.7            16.0 ± 11.1    29.3   --                 --
  PBO              Placebo        51              45.0 ± 16.3    60.8           16.0 ± 11.8     33.3   --             --                                                       
  Gottlieb         2011           USA             12 weeks       anti-IL12/23   Briakinumab     138    43.6 ± 14.3    64.5            16.1 ± 12.5    19.6   23.6 ± 16.6        18.4 ± 7.2
  anti-TNF-α       Etanercept     141             43.1 ± 12.5    69.5           17.0 ± 12.7     22.7   24.1 ± 15.0    19.4 ± 8.0                                               
  PBO              Placebo        68              44.0 ± 13.6    69.1           19.1 ± 13.2     20.6   23.8 ± 15.5    18.5 ± 6.9                                               
  Gottlieb         2003           USA             24 weeks       anti-TNF-α     Etanercept      57     48.2 ± 11.7    58              --             28     --                 --
  PBO              Placebo        55              46.5 ± 14.7    67             --              35     --             --                                                       
  Menter           2008           USA             12 weeks       anti-TNF-α     Adalimumab      814    44.1 ± 13.2    67.1            18.1 ± 11.9    27.5   25.8 ± 15.5        19.0 ± 7.1
  PBO              Placebo        398             45.4 ± 13.4    64.6           18.4 ± 11.9     28.4   25.6 ± 14.8    18.8 ± 7.1                                               
  Ohtsuki          2014           Japan           12 weeks       anti-IL17      Secukinumab     58     51.9 ± 11.8    89.7            15.6 ± 10.3    13.8   42.0 ± 23.4        26.7 ± 10.5
  PBO              Placebo        29              50.2 ± 13.6    79.3           14.1 ± 10.9     13.8   32.7 ± 16.9    21.4 ± 10.3                                              
  Ortonne          2003           France          24 weeks       ANT            Alefacept       339    --             --              19.0 ± 17.0    --     20.0 ± 19.7        13.0 ± 12.2
  PBO              Placebo        168             --             --             20.0 ± 18.5     --     23.5 ± 20.7    14.0 ± 9.7                                               
  Leonardi         2003           USA             12 weeks       anti-TNF-α     Etanercept      486    44.8 ± 0.8     65              18.6 ± 10.9    --     29.9 ± 10.6        18.4 ± 6.7
  PBO              Placebo        166             45.6 ± 1.0     63             18.4 ± 10.9     --     28.8 ± 10.4    18.3 ± 6.6                                               
  Paul             2015           France          12 weeks       anti-IL17      Secukinumab     121    46.6 ± 14.2    76.7            21.0 ± 13.5    23.3   26.4 ± 12.8        18.9 ± 6.4
  PBO              Placebo        61              43.7 ± 12.7    62.3           19.9 ± 12.2     19.7   25.7 ± 14.7    19.4 ± 6.7                                               
  Krueger          2002           USA             12 weeks       ANT            Alefacept       367    45.4 ± 15.8    71              --             --     --                 --
  PBO              Placebo        186             45 ± 14.5      68             --              --     --             --                                                       
  Mease            2000           USA             12 weeks       anti-TNF-α     Etanercept      30     46.0 ± 10.0    53              19.0 ± 7.5     100    --                 --
  PBO              Placebo        30              43.5 ± 9.7     60             17.5 ± 7.2      100    --             --                                                       
  Feldman          2005           USA             10 weeks       anti-TNF-α     Infliximab      198    --             --              --             --     --                 --
  PBO              Placebo        51              --             --             --              --     --             --                                                       
  Menter           2005           USA             12 weeks       ANT            Efalizumab      369    45.3 ± 14.2    68              19.3 ± 15.2    --     --                 --
  PBO              Placebo        187             44.9 ± 11.4    70.6           19.3 ± 13.0     --     --             --                                                       
  Leonardi         2005           USA             12 weeks       ANT            Efalizumab      328    45.5 ± 13.5    71.1            16.7 ± 14.7    --     29.9 ± 18.2        18.9 ± 11.4
  PBO              Placebo        170             41.7 ± 12.5    72.9           18.5 ± 13.7     --     29.4 ± 18.7    19.0 ± 12.0                                              
  Papp             2006           Canada          12 weeks       ANT            Efalizumab      450    45.6 ± 12.5    67.3            18.4 ± 12.1    --     27.7 ± 15.8        19.14 ± 7.5
  PBO              Placebo        236             46.3 ± 12.1    59.3           17.5 ± 11.1     --     26.8 ± 15.2    18.69 ± 7.0                                              
  Kimball          2008           USA             12 weeks       anti-IL12/23   Briakinumab     150    46.0 ± 15.0    77              18.0 ± 10.9    30     23.0 ± 12.6        19.0 ± 6.3
  PBO              Placebo        30              49.0 ± 14.4    73             21.0 ± 12.4     30     21.0 ± 9.21    16.0 ± 2.9                                               
  Reich            2005           Germany         10 weeks       anti-TNF-α     Infliximab      301    42.6 ± 11.7    69              19.1 ± 11.0    31     34.1 ± 19.0        22.9 ± 9.3
  PBO              Placebo        77              43.8 ± 12.6    79             17.3 ± 11.1     29     33.5 ± 18.0    22.8 ± 8.7                                               
  Tyring           2006           USA             12 weeks       anti-TNF-α     Etanercept      311    45.8 ± 12.8    65              20.1 ± 12.3    35     27.2 ± 18.2        18.3 ± 7.6
  PBO              Placebo        307             45.6 ± 12.1    70             19.7 ± 11.4     33     27.2 ± 17.2    18.1 ± 7.4                                               
  Lebwohl          2003           USA                            ANT            Alefacept       339    45.3 ± 14.7    62              19.0 ± 17.0    --     20.0 ± 19.7        13.2 ± 12.3
  PBO              Placebo        168             46.5 ± 15.0    65             20.0 ± 18.5     --     23.5 ± 20.7    14.3 ± 9.9                                               
  Papp             2005           Canada          12 weeks       anti-TNF-α     Etanercept      390    44.5 ± 14.7    67              18.1 ± 14.9    26     25.0 ± 17.5        16.1 ± 12.6
  PBO              Placebo        193             44.0 ± 15.5    64             17.5 ± 12.4     26     20.0 ± 21.2    16.0 ± 13.8                                              
  Torii            2010           Japan           10 weeks       anti-TNF-α     Infliximab      35     46.9 ± 13.0    62.9            14.2 ± 8.91    28.6   --                 31.9 ± 12.8
  PBO              Placebo        19              43.3 ± 12.3    73.7           11.1 ± 6.51     36.8   --             33.1 ± 15.6                                              
  Menter           2007           USA                            anti-TNF-α     Infliximab      627    44.5 ± 13.0    65              19.1 ± 11.7    28.3   28.7 ± 16.4        20.4 ± 7.5
  PBO              Placebo        208             44.4 ± 12.5    69.2           17.8 ± 10.8     26     28.4 ± 17.6    19.8 ± 7.7                                               
  Igarashi         2012           Japan           12 weeks       anti-IL12/23   Ustekinumab     126    --             75.8            17.3 ± 10.7    11.3   46.6 ± 19.7        28.7 ± 11.2
  PBO              Placebo        32              --             83.9           16.0 ± 11.2     3.1    49.8 ± 22.5    30.3 ± 11.8                                              
  Gordon           2006           USA             12 weeks       anti-TNF-α     Adalimumab      95     44.0 ± 15.5    66              18.0 ± 11.5    24     25.0 ± 19.5        14.5 ± 10.0
  PBO              Placebo        52              43.0 ± 12.5    65             19.0 ± 9.72     31     28.0 ± 17.0    16.0 ± 8.725                                             
  Krueger          2007           USA             12 weeks       anti-IL12/23   --              256    44.0 ± 13.0    81              17.3 ± 13.5    20     27.4 ± 18.1        19.0 ± 7.9
  PBO              Placebo        64              44.0 ± 14.0    72             16.9 ± 11.0     19     26.6 ± 18.4    19.9 ± 8.3                                               
  Saurat           2008           Switzerland     16 weeks       anti-TNF-α     Adalimumab      108    42.9 ± 12.6    64.8            17.9 ± 10.1    21.3   --                 20.2 ± 7.5
  AM               Methotrexate   110             41.6 ± 12.0    66.4           18.9 ± 10.2     17.3   --             19.4 ± 7.4                                               
  PBO              Placebo        53              40.7 ± 11.4    66             18.8 ± 8.70     20.8   --             19.2 ± 6.9                                               
  van de Kerkhof   2008           Netherlands     12 weeks       anti-TNF-α     Etanercept      96     45.9 ± 12.8    61.5            19.3 ± 11.3    15.6   26.5 ± 15.0        21.4 ± 9.3
  PBO              Placebo        46              43.6 ± 12.6    54.4           17.3 ± 8.20     10.9   30.3 ± 17.8    21.0 ± 8.7                                               
  Landells         2015           Multi           12 weeks       anti-IL12/23   Ustekinumab     73     14.8 ± 1.7     44.4            5.60 ± 3.80    --     31.9 ± 23.2        21.7 ± 10.4
  PBO              Placebo        37              15.6 ± 1.5     54.1           6.20 ± 5.00     --     27.4 ± 16.4    20.8 ± 8.0                                               
  Poulin           2014           Canada          16 weeks       anti-TNF-α     Adalimumab      49     49.0 ± 11.4    42.9            14.9 ± 16.3    14.3   8.90 ± 11.9        8.8 ± 8.2
  PBO              Placebo        23              54.8 ± 11.4    34.8           11.5 ± 9.94     4.3    5.10 ± 6.96    5.7 ± 4.5                                                
  Langley          2014           Canada          12 weeks       anti-IL17      Secukinumab     490    44.9 ± 13.5    69              17.4 ± 11.1    23.3   32.8 ± 19.3        22.5 ± 9.2
  PBO              Placebo        248             45.4 ± 12.6    69.4           17.3 ± 12.4     27.4   29.7 ± 15.9    21.4 ± 9.1                                               
  Ellis            2001           USA             12 weeks       ANT            Alefacept       170    44.0 ± 11.5    72.4            18.0 ± 15.0    --     25.0 ± 18.75       20.0 ± 11.5
  PBO              Placebo        59              42.0 ± 12.2    59.3           18.0 ± 9.75     --     20.0 ± 17.5    15.0 ± 17.2                                              
  Papp             2001           Canada          8 weeks        ANT            hu1124          97     44.5 ± 12.9    63              22.8 ± 12.6    --     29.4 ± 13.9        19.1 ± 7.3
  PBO              Placebo        48              42.3 ± 12.3    67             17.8 ± 10.0     --     21.5 ± 10.4    16.2 ± 4.4                                               
  Nakagawa         2016           Multi           12 weeks       anti-IL17      Brodalumab      113    46.4 ± 11.8    78.4            14.9 ± 10.9    13.5   43.7 ± 25.9        27.9 ± 14.3
  PBO              Placebo        38              46.6 ± 10.8    71.1           16.8 ± 11.4     18.4   37.8 ± 21.4    23.9 ± 8.9                                               
  Gordon           2014           USA             16 weeks       anti-TNF-α     Adalimumab      43     --             70              19.3 ± 12.8    26     26.8 ± 16.8        20.2 ± 7.6
  anti-IL12/23     Guselkumab     208             --             72             18.5 ± 12.2     25     24.6 ± 14.5    20.9 ± 8.0                                               
  PBO              Placebo        42              --             67             18.0 ± 13.3     29     27.5 ± 19.3    21.8 ± 9.9                                               
  Griffiths        2015           UK              12 weeks       anti-IL17      Ixekizumab      771    46.0 ± 13.0    66              18.0 ± 12.0    --     28.0 ± 17.0        21.0 ± 8.0
  anti-TNF-α       Etanercept     382             46.0 ± 14.0    70             18.0 ± 12.0     --     28.0 ± 17.0    21.0 ± 8.0                                               
  PBO              Placebo        193             46.0 ± 12.0    71             18.0 ± 13.0     --     29.0 ± 17.0    21.0 ± 8.0                                               
  Lebwohl          2015           USA             12 weeks       anti-IL17      Brodalumab      1222   45.0 ± 13.0    69              19.0 ± 12.0    19     27.0 ± 17.0        20.3 ± 8.2
  anti-IL12/23     Ustekinumab    300             --             --             --              --     --             --                                                       
  PBO              Placebo        309             --             --             --              --     --             --                                                       
  Thaçi            2015           Germany         16 weeks       anti-IL17      Secukinumab     337    45.2 ± 13.9    68              19.6 ± 12.9    20.5   32.6 ± 17.8        21.7 ± 8.5
  anti-IL12/23     Ustekinumab    339             44.6 ± 13.6    74.3           16.1 ± 11.2     15.9   32.0 ± 16.8    21.5 ± 8.1                                               
  Youn             2010           South Korea     12 weeks       anti-IL12/23   Ustekinumab     61     40.9 ± 12.7    82              11.9 ± 7.50    16.4   41.8 ± 24.4        25.2 ± 11.9
  PBO              Placebo        60              40.4 ± 10.1    88.3           13.9 ± 7.30     11.7   35.8 ± 21.4    22.9 ± 8.6                                               
  Zhu              2013           China           12 weeks       anti-IL12/23   Ustekinumab     160    40.1 ± 12.4    78.1            14.6 ± 8.90    8.8    35.1 ± 18.5        23.2 ± 9.5
  PBO              Placebo        162             39.2 ± 12.2    75.9           14.2 ± 8.60     8.6    35.1 ± 19.6    22.7 ± 9.5                                               
  Gordon           2010           USA             12 weeks       anti-IL12/23   Briakinumab     139    44.9 ± 12.9    66.9            16.3 ± 12.0    23.7   24.9 ± 17.8        19.4 ± 7.9
  anti-TNF-α       Etanercept     139             45.2 ± 14.8    61.2           15.2 ± 2.10     33.1   24.7 ± 13.9    18.5 ± 6.0                                               
  PBO              Placebo        72              45.0 ± 13.9    63.9           15.5 ± 11.7     20.8   22.1 ± 13.4    18.3 ± 6.4                                               
  Papp             2014           Canada          12 weeks       anti-IL12/23   Briakinumab     981    45.7 ± 13.2    67.9            18.9 ± 12.3    29.6   24.8 ± 16.3        19.1 ± 7.5
  PBO              Placebo        484             45.1 ± 13.5    70.9           19.2 ± 11.9     31     25.7 ± 16.9    19.3 ± 7.3                                               
  Papp             2015           Canada          16 weeks       anti-IL12/23   Tildrakizumab   309    43.2 ± 12.9    74              --             --     --                 --
  PBO              Placebo        46              45.9 ± 11.7    83             --              --     --             --                                                       
  Papp             2014           Multi           120 weeks      anti-IL17      Brodalumab      148    --             --              --             --     --                 --
  PBO              Placebo        33              --             --             --              --     --             --                                                       
  Krupashankar     2014           Multi           12 weeks       ANT            Itolizumab      180    40.7 ± 11.0    76.7            --             --     --                 21.3 ± 8.5
  PBO              Placebo        43              43.3 ± 13.0    74.4           --              --     --             21.9 ± 8.9                                               
  Bachelez         2015           France          12 weeks       anti-TNF-α     Etanercept      335    42.0 ± 14.0    70              18.0 ± 15.2    21     25.0 ± 20.9        19.4 ± 12.9
  PBO              Placebo        107             46.0 ± 15.0    66             17.0 ± 14.0     24     26.0 ± 17.0    19.5 ± 10.5                                              
  Micali           2015           Italy           6 weeks        anti-TNF-α     Etanercept      58     41.8 ± 13.0    65.5            --             --     --                 20.2 ± 13.7
  PBO              Placebo        62              41.5 ± 16.7    72.6           --              --     --             19.4 ± 12.6                                              
  Papp             2013           Canada          12 weeks       anti-IL17      Secukinumab     103    46.1 ± 12.6    69              19.8 ± 12.6    31     26.0 ± 19.3        21.6 ± 11.5
  PBO              Placebo        22              45.9 ± 10.8    63.6           21.4 ± 14.8     27.3   26.0 ± 18.8    21.7 ± 8.5                                               
  Reich            2013           Germany         10 weeks       anti-TNF-α     Infliximab      222    45.7 ± 13.5    68              20.5 ± 12.0    --     --                 21.5 ± 8.7
  PBO              Placebo        219             43.3 ± 13.0    71             17.5 ± 11.0     --     --             21.2 ± 7.7                                               
  Mease            2016           USA             24 weeks       PBO            Placebo         106    50.6 ± 12.3    45.3            16.0 ± 13.8    --     --                 6.2 ± 7.5
  anti-TNF-α       Adalimumab     101             48.6 ± 12.4    50.5           15.7 ± 12.7     --     --             5.5 ± 6.5                                                
  Kavanaugh        2016           USA             24 weeks       PBO            Placebo         92     47.4 ± 12.8    48.9            16.0 ± 12.6    --     28.4 ± 26.1        13.9 ± 12.5
  anti-IL12/23     Ustekinumab    164             45.7 ± 11.7    57.9           15.9 ± 11.5     --     30.1 ± 25.6    14.8 ± 12.4                                              
  Blauvelt         2016           Portland        52 weeks       anti-IL17      Secukinumab     337    45.2 ± 13.9    68              19.7 ± 12.8    20.5   --                 21.7 ± 8.5
  anti-IL12/23     Ustekinumab    339             44.6 ± 13.7    74.3           16.1 ± 11.2     15.9   --             21.5 ± 8.1                                               
  Blauvelt         2017           Multi           16 weeks       anti-IL12/23   Guselkumab      329    43.9 ± 12.74   72.9            17.9 ± 6.22    --     28.3 ± 17.1        22.1 ± 9.49
  anti-TNF-α       Adalimumab     334             42.9 ± 12.58   82.9           29.8 ± 6.48     --     28.6 ± 16.66   22.4 ± 8.97                                              
  PBO              Placebo        174             44.9 ± 12.9    83.3           28.9 ± 6.89     --     25.8 ± 15.93   20.4 ± 8.74                                              
  Kavanaugh        2017           USA             24 weeks       anti-TNF-α     Golimumab       241    45.7 ± 11.3    53.1            6.2 ± 6        --     196 ± 81.3         11 ± 9.9
  PBO              Placebo        239             46.7 ± 12.5    50.6           5.3 ± 5.9       --     198 ± 82.8     8.9 ± 9                                                  
  Lacour           2017           Multi           12 weeks       anti-IL17      Secukinumab     121    43.9 ± 14.41   71              20.6 ± 14.54   --     30.1 ± 16.66       22 ± 8.85
  PBO              Placebo        60              43.7 ± 12.74   62.3           19.9 ± 12.2     --     25.7 ± 19.7    19.4 ± 6.7                                               
  Nash             2017           Multi           24 weeks       anti-IL17      Ixekizumab      245    52.6 ± 13.6    52              15.7 ± 12.3    --     12.5               6.4 ± 7.9
  PBO              Placebo        118             51.5 ± 10.4    47             15.3 ± 12.6     --     9              5.2 ± 6.3                                                
  Papp             2017           Multi           16 weeks       anti-TNF-α     Adalimumab      77     13 ± 3.3       45              5 ± 3.8        --     17.7 ± 20.4        18.9 ± 10
  AM               MTX            37              13.4 ± 3.5     30             5.1 ± 3.8       --     30.3 ± 21.2    19.2 ± 10                                                
  Papp             2016           Multi           12 weeks       anti-IL17      Brodalumab      351    46 ± 12        73              20 ± 13        --     25.1 ± 15.3        19.4 ± 6.6
  PBO              Placebo        220             47 ± 13        73             21 ± 12         --     26.9 ± 17.1    19.7 ± 7.7                                               
  Reich            2017           USA             16 weeks       anti-IL12/23   Guselkumab      496    43.7 ± 12.2    70.4            17.9 ± 12      --     28.5 ± 16.4        21.9 ± 8.8
  anti-TNF-α       Adalimumab     284             43.2 ± 11.9    68.5           17.6 ± 11.7     --     19.1 ± 16.5    21.7 ± 9                                                 
  PBO              Placebo        284             43.3 ± 12.4    69.8           17.9 ± 11.9     ----   28 ± 16.5      21.5 ± 8                                                 
  Reich            2017           Germany         16 weeks       anti-TNF-α     Etanercept      83     40 ± 14.1      59              18.1 ± 1.7     --     29.9 ± 6.8         18.1 ± 11.7
  PBO              Placebo        84              43.4 ± 14.9    70.2           16.6 ± 12.1     --     29.5 ± 6.6     16.6 ± 12.1                                              
  Reich            2017           Germany         16 weeks       anti-IL12/23   Tildrakizumab   617    46.4 ± 13.1    67              --             --     29.7 ± 17.44       20 ± 7.85
  PBO              Placebo        155             47.9 ± 13.5    65             --              --     29.6 ± 17.28   19.3 ± 7.07                                              
  16 weeks         anti-IL12/23   Tildrakizumab   621            44.6 ± 13.6    72              --     --             34.2 ± 18.44    20.5 ± 7.63                              
  anti-TNF-α       Etanercept     313             46.4 ± 12.2    72             --              --     31.3 ± 14.75   20 ± 7.57                                                
  PBO              Placebo        156             45.8 ± 14      71             --              --     31.6 ± 16.58   20.2 ± 7.36                                              
  Reich            2017           Germany         12 weeks       anti-IL12/23   Ustekinumab     166    44 ± 13.33     67.5            18.2 ± 12      --     27.5 ± 16.7        39.4 ± 30.8
  anti-IL17        Ixekizumab     136             42.7 ± 12.7    66.2           18 ± 11.1       --     26.7 ± 16.5    42.9 ± 33.3                                              
  Paller           2008           Multi           12 weeks       anti-TNF-α     Etanercept      106    14 ± 3.25      52              --             --     --                 16.7 ± 9.9
  PBO              Placebo        105             13 ± 3.25      50             --              --     --             16.4 ± 11.175                                            
  Bachelez         2015           Multi           12 weeks       anti-TNF-α     Etanercept      335    42 ± 14        70              18 ± 15.25     21     25 ± 20.875        19.4 ± 12.9
  PBO              Placebo        107             46 ± 15        66             17 ± 14         24     26 ± 17        19.5 ± 10.55                                             
  Cai              2016           China           12 weeks       anti-TNF-α     Adalimumab      338    43.1 ± 11.91   75.1            14.8 ± 10.15   12.7   24.4 ± 3.48        28.2 ± 12
  PBO              Placebo        87              43.8 ± 12.45   66.7           15.8 ± 10.31    12.5   23.6 ± 2.86    25.6 ± 10.98                                             
  Gordon           2016           Multi           12 weeks       anti-IL17      Ixekizumab      875    46 ± 13        66.9            19 ± 12        --     --                 20 ± 7
  PBO              Placebo        431             46 ± 13        70.3           20 ± 12         --     --             20 ± 9                                                   
  Gordon           2015           Multi           16 weeks       anti-TNF-α     Adalimumab      43     50             70              91.6 ± 19.88   --     --                 20.2 ± 7.58
  PBO              Placebo        42              46.5           67             93.6 ± 22.62    --     --             21.8 ± 9.98                                              
  anti-IL12/23     Guselkumab     208             --             70             --              --     --             --                                                       
  Gottlieb         2016           Multi           16 weeks       anti-IL17      Secukinumab     137    52.4 ± 12.6    58.8            7.5 ± 8.8      --     28.8 ± 5.7         8.7 ± 10.4
  PBO              Placebo        68              50.9 ± 13      50             11.8 ± 10.4     --     28.8 ± 5.7     7.7 ± 7.3                                                
  Leonardi         2012           Multi           12 weeks       anti-IL17      Ixekizumab      58     48 ± 11        57              21 ± 12        --     22 ± 18            19.2 ± 8
  PBO              Placebo        27              45 ± 13        52             15 ± 11         --     19 ± 12        16.5 ± 5.3                                               

HPA: history of psoriatic arthritis (%); BSA: biologic systemic agents; PASI: psoriasis area and severity index; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17agents; PBO: placebo; MTX: methotrexate.

![Network diagram of all included studies. Each node represents a medicine type; the diameters of circles represent the number of people involved, and the widths of lines between two nodes represent the number of study involved in the head-to-head comparison.\
AM: anti-metabolites; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; ANT: anti-T-cell agent; anti-TNF-α: anti-tumor necrosis factor-α agent.](10.1177_1744806918762205-fig2){#fig2-1744806918762205}

NMA results for PASI reduction {#sec9-1744806918762205}
------------------------------

[Table 2](#table2-1744806918762205){ref-type="table"} showed the network comparison of different treatments for PASI reduction. In terms of PASI 75, it shows that anti-IL12/23 and anti-IL17 are significantly superior compared with PBO (OR=43.0, 95% CrI: 27.9--66.7; OR=62.2, 95% CrI: 36.6--104.6, respectively). (OR=5.9, 95% CrI: 2.5--13.7) and ANT (OR=2.44, 95% CrI: 1.3--4.8).

###### 

Network comparison of different treatments for PASI reduction in psoriasis patients.

![](10.1177_1744806918762205-table2)

                  PBO                 AM                       ANT                       Anti-IL12/23               Anti-IL17                   Anti-TNF-α
  --------------- ------------------- ------------------------ ------------------------- -------------------------- --------------------------- --------------------------
  PASI 50                                                                                                                                       
   PBO            1                   **3.16 (1.31, 7.69)**    **4.31 (2.86, 6.49)**     **49.4 (27.11, 90.02)**    **5.64 (1.11, 32.79)**      **18.36 (12.68, 26.84)**
   AM             0.32 (0.13, 0.76)   1                        1.36 (0.51, 3.63)         **15.64 (5.37, 45.60)**    1.79 (0.28, 12.81)          **5.81 (2.51, 13.74)**
   ANT            0.23 (0.15, 0.35)   0.73 (0.28, 1.97)        1                         **11.47 (5.58, 23.81)**    1.31 (0.24, 7.92)           **4.26 (2.46, 7.46)**
   Anti-IL12/23   0.02 (0.01, 0.04)   0.06 (0.02, 0.19)        0.09 (0.04, 0.18)         1                          **0.12 (0.02, 0.73)**       **0.37 (0.18, 0.75)**
   Anti-IL17      0.18 (0.03, 0.90)   0.56 (0.08, 3.60)        0.76 (0.13, 4.14)         8.67 (1.36, 49.40)         1                           3.25 (0.53, 17.64)
   Anti-TNF-α     0.05 (0.04, 0.08)   0.17 (0.07, 0.40)        0.23 (0.13, 0.41)         2.69 (1.34, 5.42)          0.31 (0.06, 1.88)           1
  PASI 75                                                                                                                                       
   PBO            1                   **3.19 (1.32, 7.69)**    **7.69 (4.31, 14.01)**    **42.95 (27.94, 66.69)**   **62.18 (36.6, 104.58)**    **18.73 (13.46, 26.58)**
   AM             0.31 (0.13, 0.76)   1                        2.41 (0.85, 7.03)         **13.60 (5.21, 35.16)**    **19.49 (7.03, 52.98)**     **5.93 (2.53, 13.74)**
   ANT            0.13 (0.07, 0.23)   0.41 (0.14, 1.17)        1                         **5.58 (2.69, 11.59)**     **8.00 (3.63, 17.46)**      **2.44 (1.25, 4.81)**
   Anti-IL12/23   0.02 (0.01, 0.04)   0.07 (0.03, 0.19)        0.18 (0.09, 0.37)         1                          1.43 (0.77, 2.64)           **0.44 (0.27, 0.71)**
   Anti-IL17      0.02 (0.01, 0.03)   0.05 (0.02, 0.14)        0.12 (0.06, 0.28)         0.70 (0.38, 1.30)          1                           **0.30 (0.17, 0.56)**
   Anti-TNF-α     0.05 (0.04, 0.07)   0.17 (0.07, 0.39)        0.41 (0.21, 0.80)         2.29 (1.40, 3.71)          3.29 (1.79, 5.99)           1
  PASI 90                                                                                                                                       
   PBO            1                   **3.78 (1.26, 11.47)**   **10.07 (2.44, 49.40)**   **41.68 (24.78, 70.11)**   **90.02 (46.53, 179.47)**   **18.92 (12.43, 29.08)**
   AM             0.26 (0.09, 0.79)   1                        2.66 (0.43, 18.17)        **11.02 (3.35, 35.52)**    **24.05 (6.69, 84.77)**     **5.00 (1.75, 14.30)**
   ANT            0.10 (0.02, 0.41)   0.38 (0.06, 2.32)        1                         4.14 (0.77, 18.73)         **9.03 (1.62, 42.52)**      1.88 (0.36, 8.25)
   Anti-IL12/23   0.02 (0.01, 0.04)   0.09 (0.03, 0.30)        0.24 (0.05, 1.30)         1                          **2.18 (1.03, 4.62)**       **0.45 (0.26, 0.80)**
   Anti-IL17      0.01 (0.01, 0.02)   0.04 (0.01, 0.15)        0.11 (0.02, 0.62)         0.46 (0.22, 0.97)          1                           **0.21 (0.10, 0.44)**
   Anti-TNF-α     0.05 (0.03, 0.08)   0.20 (0.07, 0.57)        0.53 (0.12, 2.75)         2.20 (1.25, 3.90)          4.81 (2.27, 10.07)          1

Bold: data with statistically significant difference, which is highlighted in the upper region of each outcome. PASI 50: ≥50% reduction in psoriasis area and severity index; PASI 75: ≥75% reduction in psoriasis area and severity index; PASI 90: ≥90% reduction in psoriasis area and severity index; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.

According to PASI 75, all the therapies had significantly higher ORs compared with PBO. Furthermore, anti-IL12/23, anti-IL17, and anti-TNF-α were estimated to be more effective than AM (OR=13.6, 95% CrI: 5.2--35.2; OR=19.5, 95% CrI: 7.0--53.0; OR=5.9, 95% CrI: 2.5--13.7, respectively) and ANT considering PASI 75 (OR=5.6, 95% CrI: 2.7--11.6; OR=8.0, 95% CrI: 3.6--17.5; OR=2.44, 95% CrI: 1.3--4.8, respectively).

For the comparison of treatments under PASI 90 reduction, all treatments were statistically more effective than PBO. Moreover, anti-IL17 was significantly better than other treatments. Meanwhile, it was revealed that anti-IL12/23 had significantly higher ORs than AM (OR=11.0, 95% CrI: 3.3--35.5) and anti-TNF-α (OR=2.39, 95% CrI: 1.19--4.62). Besides, anti-TNF-α had a better performance than AM (OR=2.2, 95% CrI: 1.2--3.9). The visualized result was also provided in [Figure 3](#fig3-1744806918762205){ref-type="fig"}.

![Forest plots for different treatment effects in psoriasis area and severity index reduction in psoriasis patients.\
AM: anti-metabolites; anti-IL12/23: anti-interleukin-12/23agents; anti-IL17: anti-interleukin-17 agents; ANT: anti-T-cell agent; anti-TNF-α: anti-tumor necrosis factor-α agent; PBO: placebo; PASI 50: ≥50% reduction in psoriasis area and severity index; PASI 75: ≥75% reduction in psoriasis area and severity index; PASI 90: ≥90% reduction in psoriasis area and severity index.](10.1177_1744806918762205-fig3){#fig3-1744806918762205}

NMA result for DLQI and PGA {#sec10-1744806918762205}
---------------------------

[Table 3](#table3-1744806918762205){ref-type="table"} showed the network comparison of different treatments for DLQI and PGA. In view of DQLI, only two drugs, anti-IL12/23 and anti-TNF-α were superior compared with PBO (OR=13.8, CrI: 4.6--23.3; OR=9.6, CrI: 1.2--18.1, respectively). Considering PGA, all drugs were superior compared with PBO, and anti-IL12/23, anti-IL17, and anti-TNF-α had better PGA compared with AM (OR=6.62, 95% CrI: 1.68--25.79; OR=21.54, 95% CrI: 4.57--101.49; OR=4.06, 95% CrI: 1.20--13.60, respectively) and ANT (OR=11.94, 95% CrI: 4.48--31.82; OR=38.36, 95% CrI: 11.47--134.29; OR=7.32, 95% CrI: 2.8--18.73, respectively). In addition, anti-IL17 was estimated to be superior to anti-TNF-α (OR=5.31, 95% CrI: 1.93--14.88). The forest plots were presented in [Figure 4](#fig4-1744806918762205){ref-type="fig"}.

###### 

Network comparison of different treatments for Dermatology Life Quality Index and Physician's Global Assessment in psoriasis patients.

![](10.1177_1744806918762205-table3)

                                   PBO                      AM                       ANT                     Anti-IL12/23               Anti-IL17                   Anti-TNF-α
  -------------------------------- ------------------------ ------------------------ ----------------------- -------------------------- --------------------------- --------------------------
  Dermatology Life Quality Index                                                                                                                                    
   PBO                             1                        3.34 (−18.48, 24.82)     2.75 (−29.15, 34.17)    **13.75 (4.61, 23.03)**    7.59 (−13.44, 28.50)        **9.61 (1.15, 18.11)**
   AM                              −3.34 (−24.82, 18.48)    1                        −0.55 (−39.1, 37.58)    10.44 (−12.65, 33.71)      4.29 (−25.36, 33.83)        6.25 (−14.6, 27.26)
   ANT                             −2.75 (−34.17, 29.15)    0.55 (−37.58, 39.10)     1                       10.98 (−21.69, 44.20)      4.80 (−33.03, 42.39)        6.83 (−25.58, 39.77)
   Anti-IL12/23                    −13.75 (−23.03, −4.61)   −10.44 (−33.71, 12.65)   −10.98 (−44.2, 21.69)   1                          −6.15 (−29.1, 16.45)        −4.13 (−15.66, 7.49)
   Anti-IL17                       −7.59 (−28.5, 13.44)     −4.29 (−33.83, 25.36)    −4.80 (−42.39, 33.03)   6.15 (−16.45, 29.10)       1                           2.02 (−19.49, 23.74)
   Anti-TNF-α                      −9.61 (−18.11, −1.15)    −6.25 (−27.26, 14.60)    −6.83 (−39.77, 25.58)   4.13 (−7.49, 15.66)        −2.02 (−23.74, 19.49)       1
  Physician's Global Assessment                                                                                                                                     
   PBO                             1                        **4.48 (1.25, 16.28)**   **2.48 (1.14, 5.53)**   **29.67 (16.78, 52.98)**   **95.58 (38.09, 252.14)**   **18.17 (10.80, 30.88)**
   AM                              0.22 (0.06, 0.80)        1                        0.55 (0.12, 2.51)       **6.62 (1.68, 25.79)**     **21.54 (4.57, 101.49)**    **4.06 (1.20, 13.60)**
   ANT                             0.40 (0.18, 0.88)        1.80 (0.40, 8.17)        1                       **11.94 (4.48, 31.82)**    **38.86 (11.47, 134.29)**   **7.32 (2.80, 18.73)**
   Anti-IL12/23                    0.03 (0.02, 0.06)        0.15 (0.04, 0.59)        0.08 (0.03, 0.22)       1                          **3.25 (1.21, 8.94)**       0.61 (0.32, 1.20)
   Anti-IL17                       0.01 (0.00, 0.03)        0.05 (0.01, 0.22)        0.03 (0.01, 0.09)       0.31 (0.11, 0.83)          1                           **0.19 (0.07, 0.52)**
   Anti-TNF-α                      0.06 (0.03, 0.09)        0.25 (0.07, 0.84)        0.14 (0.05, 0.36)       1.63 (0.84, 3.16)          5.31 (1.93, 14.88)          1

Bold: data with statically significant difference, which is highlighted in the upper region of each outcome. AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.

![Forest plots for different treatment effects of Dermatology Life Quality Index and Physician's Global Assessment in psoriasis patients.\
AM: anti-metabolites; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; ANT: anti-T-cell agent; anti-TNF-α: anti-tumor necrosis factor-α agent; PBO: placebo; DLQI: Dermatology Life Quality Index; PGA: Physician's Global Assessment -- minimal or cleared.](10.1177_1744806918762205-fig4){#fig4-1744806918762205}

NMA result for AEs {#sec11-1744806918762205}
------------------

[Table 4](#table4-1744806918762205){ref-type="table"} showed the network comparison of different treatments for adverse events. According to all adverse events (AAE), only anti-IL17 showed a significant result that it had more AAE than PBO (OR=0.68, 95% CrI: 0.48--0.97). In view of incidence of infection, anti-IL12/23, anti-IL17, and anti-TNF-α showed more infection cases than PBO (OR=1.28, 95% CrI: 1.11--1.48; OR=1.32, 95% CrI: 1.05--1.68; OR=1.28, 95% CrI: 1.12--1.48, respectively). Besides, anti-TNF-α was associated with statistically significant increased odds of nasopharyngitis compared with PBO (OR=0.64, 95% CrI: 0.42--0.94). In view of headache, few of them demonstrated a significant difference. ANT, anti-IL17, and anti-TNF-α was assessed to be worse compared with PBO (OR=1.54, 95% CrI: 1.14--2.10; OR=1.77, 95% CrI: 1.12--2.83; OR=1.40, 95% CrI: 1.06--1.88, respectively). As for URTI, only AM was associated with statistically stronger URTI compared with PBO and all the other inventions. Meanwhile, the network comparisons for incidence of withdrawal due to the AE showed that compared with patients using PBO, patients using IL12/23 or TNF-α had statistically higher possibility to keep on (OR=0.64, 95% CrI: 0.42--0.98; OR=0.64, 95% CrI: 0.46--0.92, respectively). In addition, AM was associated with higher withdrawal probability than other inventions. The forest plots of the random-effects model were shown in [Figure 5](#fig5-1744806918762205){ref-type="fig"}.

###### 

Network comparison of different treatments for adverse events in psoriasis patients.

![](10.1177_1744806918762205-table4)

                                      PBO                     AM                       ANT                     Anti-IL12/23            Anti-IL17               Anti-TNF-α              
  ----------------------------------- ----------------------- ------------------------ ----------------------- ----------------------- ----------------------- ----------------------- ----------------
  All adverse events                                                                                                                                                                   
   PBO                                1                       1.02(0.63, 1.67)         1.15 (0.96, 1.36)       **1.28 (1.11, 1.48)**   **1.32 (1.05, 1.68)**   **1.28 (1.12, 1.48)**   **Infection**
   AM                                 0.79 (0.39, 1.55)       1                        1.12 (0.66, 1.90)       1.25 (0.76, 2.05)       1.30 (0.75, 2.20)       1.25 (0.78, 2.03)       
   ANT                                1.21 (0.76, 1.90)       1.54 (0.67, 3.53)        1                       1.11 (0.89, 1.40)       1.15 (0.86, 1.57)       1.12 (0.89, 1.40)       
   Anti-IL12/23                       0.88 (0.67, 1.15)       1.12 (0.55, 2.29)        0.73 (0.43, 1.23)       1                       1.04 (0.84, 1.27)       1.01 (0.84, 1.19)       
   Anti-IL17                          **0.68 (0.48, 0.97)**   0.87 (0.40, 1.86)        0.57 (0.32, 1.00)       0.77 (0.53, 1.13)       1                       0.97 (0.75, 1.26)       
   Anti-TNF-α                         0.82 (0.63, 1.08)       1.05 (0.55, 2.01)        0.68 (0.40, 1.16)       0.93 (0.68, 1.30)       1.21 (0.79, 1.86)       1                       
  Nasopharyngitis                                                                                                                                                                      
   PBO                                1                       1.58 (0.73, 3.32)        **1.54 (1.14, 2.10)**   1.48 (0.97, 2.27)       **1.77 (1.12, 2.83)**   **1.40 (1.06, 1.88)**   **Headache**
   AM                                 0.81 (0.31, 2.12)       1                        0.98 (0.44, 2.23)       0.94 (0.41, 2.23)       1.12 (0.47, 2.75)       0.90 (0.44, 1.84)       
   ANT                                0.76 (0.18, 3.13)       0.93 (0.17, 5.26)        1                       0.96 (0.57, 1.63)       1.14 (0.66, 2.01)       0.91 (0.61, 1.38)       
   Anti-IL12/23                       0.66 (0.43, 0.98)       0.81 (0.29, 2.25)        0.86 (0.2, 3.82)        1                       1.19 (0.72, 2.01)       0.95 (0.58, 1.54)       
   Anti-IL17                          0.70 (0.44, 1.07)       0.85 (0.30, 2.44)        0.91 (0.21, 4.10)       1.06 (0.64, 1.77)       1                       0.8 (0.46, 1.35)        
   Anti-TNF-α                         **0.64 (0.42, 0.94)**   0.79 (0.31, 1.95)        0.84 (0.19, 3.71)       0.97 (0.59, 1.60)       0.91 (0.52, 1.62)       1                       
  Upper respiratory tract infection                                                                                                                                                    
   PBO                                1                       2.25 (0.91, 5.81)        0.70 (0.44, 1.13)       **0.64 (0.42, 0.98)**   0.73 (0.45, 1.19)       **0.64 (0.46, 0.92)**   **Withdrawal**
   AM                                 **0.11 (0.02, 0.48)**   1                        **0.31 (0.11, 0.86)**   **0.28 (0.10, 0.75)**   **0.32 (0.11, 0.89)**   **0.29 (0.12, 0.67)**   
   ANT                                1.01 (0.39, 2.51)       **9.12 (1.63, 62.18)**   1                       0.90 (0.49, 1.70)       1.03 (0.53, 1.99)       0.91 (0.52, 1.65)       
   Anti-IL12/23                       0.83 (0.61, 1.12)       **7.46 (1.70, 41.26)**   0.82 (0.31, 2.18)       1                       1.14 (0.66, 1.97)       1.01 (0.62, 1.67)       
   Anti-IL17                          0.66 (0.41, 1.00)       **5.93 (1.31, 39.25)**   0.66 (0.23, 1.82)       0.80 (0.49, 1.26)       1                       0.89 (0.51, 1.58)       
   Anti-TNF-α                         0.90 (0.71, 1.15)       **8.17 (1.95, 45.60)**   0.90 (0.34, 2.39)       1.09 (0.77, 1.57)       1.38 (0.86, 2.29)       1                       

Bold: data with statically significant difference; in the upper regions, columns are compared with rows, while lower regions are opposite. AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.

![Forest plots for different treatment effects of adverse events in psoriasis patients.\
AM: anti-metabolites; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; ANT: anti-T-cell agent; anti-TNF-α: anti-tumor necrosis factor-α agent; PBO: placebo.](10.1177_1744806918762205-fig5){#fig5-1744806918762205}

Ranking of treatments {#sec12-1744806918762205}
---------------------

The SUCRA values for different treatments for all outcomes was calculated in order to determine the best method for curing psoriasis, and the calculated numbers were listed in [Table 5](#table5-1744806918762205){ref-type="table"}. The result showed that anti-IL12/23 had better efficacy in ≥50% reduction in PASI (0.997) and led to better Dermatology Life Quality (0.842), but for better efficacy in PASI, it is indicated that anti-IL17 had the most possibility to rank the first among all six drugs (PASI 75: 0.980, PASI 90: 0.995, PGA: 0.998). Meanwhile, anti-TNF-α had good performance in PASI 50, 75, and 90. However, AM and ANT showed less efficacy. As for ranking of incidence of AE, it showed that none of the interventions were better than PBO except for ANT in AAE outcome. And anti-IL17 showed worse effect in both AAE and infection (AAE: 0.281, infection: 0.352).

###### 

Surface under the cumulative ranking curve (SUCRA) values for different treatments for all outcomes in psoriasis patients.

![](10.1177_1744806918762205-table5)

  Outcomes          PBO     AM      ANT     Anti-IL12/23   Anti-IL17   Anti-TNF-α
  ----------------- ------- ------- ------- -------------- ----------- ------------
  PASI 50           0.171   0.421   0.520   0.997          0.571       0.819
  PASI 75           0.167   0.341   0.493   0.854          0.980       0.666
  PASI 90           0.168   0.356   0.518   0.829          0.995       0.632
  DLQI              0.342   0.495   0.506   0.842          0.617       0.699
  PGA               0.171   0.465   0.368   0.823          0.998       0.676
  AAE               0.782   0.474   0.904   0.580          0.281       0.480
  Infection         0.910   0.761   0.643   0.427          0.352       0.407
  Nasopharyngitis   0.874   0.643   0.588   0.454          0.517       0.423
  Headache          0.972   0.501   0.495   0.554          0.363       0.615
  URTI              0.861   0.171   0.745   0.602          0.415       0.706
  Withdrawal        0.359   0.179   0.702   0.800          0.669       0.791

PASI 50: ≥50% reduction in psoriasis area and severity index; PASI 75: ≥75% reduction in psoriasis area and severity index; PASI 90: ≥90% reduction in psoriasis area and severity index; DLQI: Dermatology Life Quality Index; PGA: Physician's Global Assessment -- minimal or cleared; AAE: all adverse events; URTI: upper respiratory tract infection; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.

Inconsistency analysis {#sec13-1744806918762205}
----------------------

The direct and indirect evidences for each comparison under all outcomes, as well as network results, were presented in [Table 6](#table6-1744806918762205){ref-type="table"}. *p*\<0.05 suggested a significant inconsistency between direct and indirect evidence. Overall, no inconsistency was found for each comparison under all outcomes (all *p*\>0.05), which indicated reliable results of the current NMA.

###### 

Comparison of direct and indirect evidences of treatments for psoriasis.

![](10.1177_1744806918762205-table6)

  Study                           PASI 75   PGA                 AAE     Nasopharyngitis     Headache   URTI                Withdrawal                                                                                       
  ------------------------------- --------- ------------------- ------- ------------------- ---------- ------------------- ------------ ------------------- ------- ------------------- ------- ------------------- ------- -------------------
  *AM vs. PBO*                                                                                                                                                                                                              
  Direct                                    2.50 (0.70, 9.80)           3.70 (0.35, 36.0)              1.10 (0.33, 4.00)                1.20 (0.28, 5.90)           1.20 (0.32, 5.00)           --                          4.30 (0.45200)
  Indirect                        0.544     4.50 (1.20, 17.0)   0.756   5.50 (1.00, 30.0)   0.988      1.10 (0.48, 2.70)   0.989        1.20 (0.27, 5.20)   0.555   2.10 (0.72, 5.60)   --      --                  0.538   2.00 (0.73, 5.90)
  Network                                   3.10 (1.30, 7.40)           4.40 (1.02, 17.0)              1.30 (0.65, 2.60)                1.20 (0.47, 3.20)           1.60 (0.69, 3.30)           --                          2.30 (0.89, 5.90)
  *Anti-IL12/23 vs. PBO*                                                                                                                                                                                                    
  Direct                                    51.0 (30.0, 86.0)           --                             1.10 (0.76, 1.50)                1.30 (0.82, 2.50)           1.10 (0.69, 2.00)           1.10 (0.81, 1.60)           0.65 (0.40, 1.10)
  Indirect                        0.146     16.0 (3.70, 71.0)   --      --                  0.403      1.60 (0.68, 3.80)   0.604        1.40 (0.66, 5.20)   0.246   2.10 (0.86, 5.10)   0.433   1.60 (0.69, 4.00)   0.642   0.89 (0.26, 2.90)
  Network                                   43.0 (27.0, 67.0)           --                             1.10 (0.87, 1.50)                1.50 (1.00, 2.30)           1.50 (0.99, 2.20)           1.20 (0.89, 1.70)           0.65 (0.42, 0.99)
  *Anti-IL17 vs. PBO*                                                                                                                                                                                                       
  Direct                                    50.0 (28.0, 86.0)           --                             1.60 (1.10, 2.50)                1.60 (0.96, 2.50)           2.00 (1.20, 3.50)           1.70 (1.00, 3.00)           0.83 (0.47, 1.50)
  Indirect                        0.101     140 (42.0, 960)     --      --                  0.356      1.10 (0.55, 2.30)   0.558        1.20 (0.49, 2.70)   0.396   1.30 (0.52, 3.10)   0.494   1.20 (0.54, 2.70)   0.394   0.49 (0.17, 1.50)
  Network                                   62.0 (37.0, 130)            --                             1.50 (1.00, 2.10)                1.40 (0.94, 2.20)           1.80 (1.10, 2.80)           1.50 (1.00, 2.50)           0.73 (0.45, 1.20)
  *Anti-IL17 vs. Anti-IL12/23*                                                                                                                                                                                              
  Direct                                    2.30 (0.85, 6.50)           2.10 (0.43, 11.0)              1.10 (0.62, 1.80)                0.82 (0.39, 1.80)           0.96 (0.46, 2.00)           1.00 (0.49, 2.30)           0.82 (0.36, 1.90)
  Indirect                        0.224     1.10 (0.51, 2.30)   0.463   4.60 (1.20, 20.0)   0.266      1.60 (0.94, 2.80)   0.568        0.87 (0.54, 2.20)   0.399   1.50 (0.72, 3.30)   0.500   1.50 (0.80, 2.80)   0.387   1.30 (0.65, 2.60)
  Network                                   1.40 (0.76, 2.60)           3.30 (1.20, 9.10)              1.30 (0.88, 1.90)                0.93 (0.57, 1.60)           1.20 (0.60, 1.50)           1.30 (0.79, 2.10)           1.10 (0.64, 2.00)
  *Anti-TNF-α vs. Anti-IL12/23*                                                                                                                                                                                             
  Direct                                    0.40 (0.21, 0.79)           0.51 (0.22, 1.10)              1.10 (0.69, 1.80)                1.00 (0.47, 2.20)           --                          0.77 (0.45, 1.30)           1.10 (0.50, 2.30)
  Indirect                        0.588     0.53 (0.25, 1.10)   0.511   0.73 (0.29, 1.80)   0.840      1.00 (0.54, 1.90)   0.916        1.00 (0.48, 2.10)   --      --                  0.470   1.00 (0.63, 1.60)   0.871   1.00 (0.54, 2.10)
  Network                                   0.44 (0.27, 0.73)           0.62 (0.31, 1.20)              1.10 (0.77, 1.50)                1.00 (0.62, 1.70)           --                          0.91 (0.62, 1.30)           1.00 (0.63, 1.60)
  *Anti-TNF-α vs. Anti-IL17*                                                                                                                                                                                                
  Direct                                    0.19 (0.03, 1.00)           0.19 (0.02, 1.60)              --                               --                          --                          --                          0.51 (0.13, 1.90)
  Indirect                        0.568     0.33 (0.18, 0.65)   0.931   0.17 (0.05, 0.54)   --         --                  --           --                  --      --                  --      --                  0.368   1.00 (0.56, 1.90)
  Network                                   0.30 (0.17, 0.55)           0.18 (0.06, 0.54)              --                               --                          --                          --                          0.89 (0.52, 1.60)

URTI: upper respiratory tract infection; PASI 75: ≥75% reduction in psoriasis area and severity index; PGA: Physician's Global Assessment -- minimal or cleared; AAE: all adverse events; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.

Discussion {#sec14-1744806918762205}
==========

Undoubtedly, as the NMA results revealed, all included therapies showed significant efficacy when compared with PBO in terms of all the efficacy outcomes except for DLQI, which in general corresponded to the results of previous RCTs. Meanwhile, the efficacy and safety of these therapies were certainly different from each other.

First of all, as was shown in the NMA results, anti-IL12/23 was proved to be the most ideal therapy among the included therapies. Its excellent efficacy as well as mild AEs was revealed. Additionally, its extraordinary efficacy and safety were also proved by previous RCTs, which corresponded with the results of previous RCT studies.^[@bibr25-1744806918762205],[@bibr29-1744806918762205]^ Ustekinumab, an antibody agent binding to the shared p40 subunit of IL 12/23, was the most widely researched agent among the therapies mentioned above. It bound to the interleukins specifically and prevented their binding with respective receptors, thus blocked the downstream signaling cascades.^[@bibr25-1744806918762205]^ Meanwhile, briakinumab, another research focus with analogous structure and function with ustekinumab, also showed an excellent performance clinically. Tildrakizumab and guselkumab are also experimental monoclonal antibodies (Statement on a Nonproprietary Name Adopted by the USAN Council---Tildrakizumab; Statement on A Nonproprietary Name Adopted by the USAN Council---Guselkumab) designed to block IL-23. However, such agents still required more research to promote its clinical appliance.

Second, anti-IL17 showed a satisfactory efficacy performance in this NMA. It was revealed that this therapy had a similar efficacy with anti-IL12/23. These anti-IL17 monoclonal antibody agents including ixekizumab, brodalumab, and secukinumab selectively bind to the IL 17 and neutralize the bioactivity of this cytokine.^[@bibr22-1744806918762205]^ Though its efficacy was excellent, the safety of this therapy was not very good.

Third, ANT showed a weaker efficacy; however, its total AE ranked the first among the relevant therapy, and as a result, it can be regarded as a milder treatment in the clinical appliance.

Fourth, anti-TNF-α showed weaker efficacy than anti-IL-17 or anti-IL12/23 accompanied with a stronger AE; as a result, it was not recommended in this NMA research. As revealed in the introduction part, interleukins stimulate T-cells to produce TNF causing psoriasis. These biological agents work on the stimulation interleukins, the producer T-cells, and the final production TNF, respectively. The selectivity of these therapies gave them totally different mechanism and excellent efficacy. However, infection, the major AE of the above-mentioned biological agents according to the NMA results and previous studies,^[@bibr88-1744806918762205],[@bibr89-1744806918762205]^ was still a severe problem to be solved. Additionally, a number of relevant biological agents were still at the stage of laboratory research, requiring more clinical studies and appliances.

Finally, AM did not work well in both efficacy and AE outcomes, which made is the least satisfactory therapy.

In this NMA research, there also existed some limitations. First of all, most of included studies reported the latest biological agents comparing with PBO or traditional therapy AM. However, direct RCT studies between these different treatments were still required for the unchallengeable authority of clinical experimental data. Besides, this NMA did not evaluate the treatment of mild psoriasis and topical therapies indicated for patients whose affected area is less than 10% of the BSA.^[@bibr90-1744806918762205],[@bibr91-1744806918762205]^ The majority of this research and relevant works focused on severe psoriasis, and little attention was paid to the topical therapies like vitamin D and emollient. Finally, in this NMA, we divided the drugs treating psoriasis into five classes and regarded each whole class as a therapy; the efficacy and safety performance of interclass drug was not revealed in this NMA.

In conclusion, the efficacy and safety of some therapies of psoriasis were evaluated comprehensively and quantitatively in this NMA; monoclonal antibody agents of IL 12/23 and IL 17 were two recommended agents according to the results, while anti-IL17 should be used in caution since it has severe side effects.
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